{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:04:55Z","timestamp":1761239095371},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Minimal change disease (MCD), a pathological type of nephrotic syndrome (NS), can occur in patients with tumors. We report two adult cases of MCD associated with papillary thyroid carcinoma (PTC), known to be extremely rare in adults.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 35-year-old female patient was simultaneously diagnosed with MCD and PTC. The MCD was effectively treated with thyroidectomy and prednisone.In addition, a 50-year-old male patient, who had been diagnosed with PTC three years prior, had MCD confirmed by renal biopsy. The patient achieved complete remission following treatment with tacrolimus and rituximab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present case report describes and discusses the diagnostic and treatment processes employed in these two patients. Clinicians need to be aware of the renal effects of treating patients with solid tumors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-023-03252-9","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T12:01:50Z","timestamp":1688558510000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Minimal change disease with papillary thyroid carcinoma: a report of two adult cases"],"prefix":"10.1186","volume":"24","author":[{"given":"Juanjuan","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zexuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zedong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuanzhuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"issue":"4","key":"3252_CR1","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ekir.2022.03.001","volume":"7","author":"RJ Maas","year":"2022","unstructured":"Maas RJ, Nijenhuis T, van der Vlag J. Minimal change disease: more than a podocytopathy? Kidney Int Rep. 2022;7(4):675\u20137.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"3252_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3322\/caac.21636","volume":"1","author":"MH Rosner","year":"2021","unstructured":"Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: the intersections between the kidney and cancer. CA Cancer J Clin. 2021;1(1):47\u201377.","journal-title":"CA Cancer J Clin"},{"key":"3252_CR3","doi-asserted-by":"publisher","first-page":"985925","DOI":"10.3389\/fimmu.2022.985925","volume":"13","author":"B Seitz-Polski","year":"2022","unstructured":"Seitz-Polski B, Audard V, Ghiggeri GM, Tomas NM. Editorial: Immune dysfunction in nephrotic syndrome - recent advances and new roads ahead. Front Immunol. 2022;13:985925.","journal-title":"Front Immunol"},{"issue":"4","key":"3252_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1053\/j.ajkd.2016.09.027","volume":"69","author":"T Koopman","year":"2017","unstructured":"Koopman T, Niedlich-den Herder C, Stegeman CA, Links TP, Bijzet J, Hazenberg BPC, et al. Kidney involvement in systemic calcitonin amyloidosis associated with medullary thyroid carcinoma. Am J Kidney Dis. 2017;69(4):546\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"3252_CR5","first-page":"183","volume":"30","author":"ST Han","year":"2011","unstructured":"Han ST, Choi SO, Song SH, Kim JS, Eom MS, Lee JI, et al. Membranoproliferative glomerulonephritis associated with papillary thyroid carcinoma. Korean J Nephrol. 2011;30(2):183\u20136.","journal-title":"Korean J Nephrol"},{"issue":"5","key":"3252_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.4103\/ijn.IJN_215_18","volume":"29","author":"N Pattanashetti","year":"2019","unstructured":"Pattanashetti N, Kapatia G, Nada R, Gupta KL, Ramachandran R. Association of membranoproliferative glomerulonephritis with papillary carcinoma thyroid. Indian J Nephrol. 2019;29(5):368\u20139.","journal-title":"Indian J Nephrol"},{"key":"3252_CR7","first-page":"e11","volume":"6","author":"FE Tabar","year":"2020","unstructured":"Tabar FE, Fallah H, Akbari R. Focal segmental glomerulosclerosis associated with papillary thyroid carcinoma in a patient with polycystic kidney disease. J Ren Endocrinol. 2020;6:e11.","journal-title":"J Ren Endocrinol"},{"issue":"9","key":"3252_CR8","first-page":"714","volume":"57","author":"P Liu","year":"2019","unstructured":"Liu P, Tian M, Wei L, Cao GH, Zhang SF, Liu CH. [A case of minimal-change nephrotic syndrome complicated with thyroid carcinoma in children]. Zhonghua Er Ke Za Zhi. 2019;57(9):714\u20135.","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"3252_CR9","doi-asserted-by":"publisher","first-page":"1132259","DOI":"10.3389\/fmed.2023.1132259","volume":"10","author":"X Cai","year":"2023","unstructured":"Cai X, Wu Y, Wan Q, Zhang X. Minimal change disease associated with thyroid cancer: a case report. Front Med (Lausanne). 2023;10:1132259.","journal-title":"Front Med (Lausanne)"},{"issue":"5\u20136","key":"3252_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1159\/000083474","volume":"21","author":"K Taniguchi","year":"2004","unstructured":"Taniguchi K, Fujioka H, Torashima Y, Yamaguchi J, Izawa K, Kanematsu T. Rectal cancer with paraneoplastic nephropathy: association of vascular endothelial growth factor. Dig Surg. 2004;21(5\u20136):455\u20137.","journal-title":"Dig Surg"},{"issue":"20","key":"3252_CR11","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.12998\/wjcc.v8.i20.4883","volume":"8","author":"CH Yang","year":"2020","unstructured":"Yang CH, Chen KT, Lin YS, Hsu CY, Ou YC, Tung MC. Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: a case report. World J Clin Cases. 2020;8(20):4883\u201394.","journal-title":"World J Clin Cases"},{"issue":"1","key":"3252_CR12","doi-asserted-by":"publisher","first-page":"6421","DOI":"10.1038\/s41598-019-42905-4","volume":"9","author":"LZ Li","year":"2019","unstructured":"Li LZ, Hu Y, Ai SL, Cheng L, Liu J, Morris E, et al. The relationship between thyroid dysfunction and nephrotic syndrome: a clinicopathological study. Sci Rep. 2019;9(1):6421.","journal-title":"Sci Rep"},{"issue":"18","key":"3252_CR13","doi-asserted-by":"publisher","first-page":"e130249","DOI":"10.1172\/jci.insight.130249","volume":"4","author":"V Benedetti","year":"2019","unstructured":"Benedetti V, Lavecchia AM, Locatelli M, Brizi V, Corna D, Todeschini M, et al. Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytes. JCI Insight. 2019;4(18):e130249.","journal-title":"JCI Insight"},{"issue":"2","key":"3252_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/jch.14152","volume":"23","author":"SS Jankauskas","year":"2021","unstructured":"Jankauskas SS, Morelli MB, Gambardella J, Lombardi A, Santulli G. Thyroid hormones regulate both cardiovascular and renal mechanisms underlying hypertension. J Clin Hypertens (Greenwich). 2021;23(2):373\u201381.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"3252_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2174\/1570161115999170207114706","volume":"15","author":"FD Mario","year":"2017","unstructured":"Mario FD, Pofi R, Gigante A, Rivoli L, Rosato E, Isidori AM, et al. Hypothyroidism and nephrotic syndrome: why, when and how to treat. Curr Vasc Pharmacol. 2017;15(5):398\u2013403.","journal-title":"Curr Vasc Pharmacol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03252-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03252-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03252-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T12:02:41Z","timestamp":1688558561000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03252-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3252"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03252-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"27 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any study requiring ethical approval. Human data used in the present study were obtained from public databases in an anonymized and aggregated form. The results are appropriately placed in the context of prior and existing research. All authors have been personally and actively involved in substantial work leading to the paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients provided written informed consent for their medical information to be presented in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"202"}}